{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:51:29Z","timestamp":1785876689051,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s13555-023-01063-2","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:03:36Z","timestamp":1700640216000},"page":"3209-3220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-520X","authenticated-orcid":false,"given":"Maryanne M.","family":"Senna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-5124","authenticated-orcid":false,"given":"Ohsang","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-9689","authenticated-orcid":false,"given":"Bianca M.","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-1428","authenticated-orcid":false,"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-6721","authenticated-orcid":false,"given":"Susan","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-1152","authenticated-orcid":false,"given":"Yves","family":"Dutronc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, et\u00a0al. Alopecia areata. Nat Rev Dis Prim. 2017;3:17011.","journal-title":"Nat Rev Dis Prim"},{"issue":"4","key":"1063_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):806-812.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1063_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556-558.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1063_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, et\u00a0al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76.","journal-title":"J Patient Rep Outcomes"},{"issue":"4","key":"1063_CR5","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1111\/ajd.12840","volume":"59","author":"P Fernandez-Gonzalez","year":"2018","unstructured":"Fernandez-Gonzalez P, et\u00a0al. Spontaneous hair regrowth in eight patients with severe alopecia areata. Australas J Dermatol. 2018;59(4):e318\u20139.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"1063_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, et\u00a0al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"1063_CR7","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, et\u00a0al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"3","key":"1063_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, et\u00a0al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1063_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, et\u00a0al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1063_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, et\u00a0al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1063_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, et\u00a0al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327.","journal-title":"Br J Dermatol"},{"key":"1063_CR12","unstructured":"King B, et\u00a0al. Safety analysis of baricitinib in adult patients with severe alopecia areata from 2 randomized clinical trials over a median of 1.6 years and up to 3.6 years of exposure. In: American Academy of Dermatology 81st annual meeting."},{"issue":"6","key":"1063_CR13","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaad.2018.11.037","volume":"80","author":"LY Liu","year":"2019","unstructured":"Liu LY, King BA. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. J Am Acad Dermatol. 2019;80(6):1778\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1063_CR14","doi-asserted-by":"publisher","first-page":"2227299","DOI":"10.1080\/09546634.2023.2227299","volume":"34","author":"BM Piraccini","year":"2023","unstructured":"Piraccini BM, et\u00a0al. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatol Treat. 2023;34(1):2227299.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"1063_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2010.10011.x","volume":"164","author":"U Blume-Peytavi","year":"2011","unstructured":"Blume-Peytavi U, et\u00a0al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164(1):5\u201315.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1063_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, et\u00a0al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1063_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, et\u00a0al. Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1063_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","volume":"21","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, et\u00a0al. Development of Clinician-Reported Outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725\u201332.","journal-title":"Am J Clin Dermatol"},{"key":"1063_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1063_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","volume":"5","author":"MM Chren","year":"2001","unstructured":"Chren MM, et\u00a0al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105\u201310.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1063_CR21","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jisp.2020.04.006","volume":"20","author":"LY Liu","year":"2020","unstructured":"Liu LY, King BA, Ko JM. Eyebrows are important in the treatment of alopecia areata. J Investig Dermatol Symp Proc. 2020;20(1):S37\u201340.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1063_CR22","unstructured":"Okhovat JP, et\u00a0al. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2019."},{"key":"1063_CR23","unstructured":"Piraccini BM, et\u00a0al. The contribution of hair regrowth to health-related quality of life improvement in patients with alopecia areata treated with baricitinib or placebo. In: World congress of hair research 2022, 2022."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01063-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T17:22:09Z","timestamp":1701364929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01063-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01063-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Susan Ball, Yuxin Ding, Yun-Fei Chen, and Yves Dutronc are all employees and shareholders of Eli Lilly and Company. Brett King has received fees from Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka\/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, TWI Biotechnology Inc, and Viela Bio; he has served on speaker bureaus for Abbvie, Incyte, Eli Lilly, Pfizer, Regeneron and Sanofi Genzyme; he has presented data at a scientific venue on behalf of Eli Lilly and Company. Ohsang Kwon has received grants for research from Eli Lilly and Company, Pfizer, AddPharma, and CKD Pharm. Rodney Sinclair has received consultancy fees from Eli Lilly and Company, Pfizer, Reistone Pharmaceuticals, Abbvie and Samson Clinical and has presented data at a scientific venue on behalf of Eli Lilly and Company, Pfizer and Abbvie. Bianca Maria Piraccini has received consultancy fees from Eli Lilly and Company, Pfizer, ISDIN, Almirall, and Vichy, has received payment for presentations or speaker bureaus from Eli Lilly and Company and Pfizer, and has participated on advisory boards for Eli Lilly and Company and Pfizer. Maryanne Senna\u00a0has received consultancy fees from Arena Pharmaceuticals, Eli Lilly and Company, and Pfizer, has been a speaker for Pfizer and Eli Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}